Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1195042 | 0.98 | PARP1 (0.32) | PARP1 | |
| SCHEMBL221429 | 0.89 | LMNA (0.35) | — | |
| SCHEMBL7132721 | 0.85 | CA1 (0.34) | PARP1 | |
| SCHEMBL18997579 | 0.85 | CHRNB2 (0.33) | PARP1DPP4 | |
| SCHEMBL21169298 | 0.85 | CHRNB2 (0.33) | PARP1DPP4 | |
| SCHEMBL30576811 | 0.84 | USP2 (0.40) | PARP1 | |
| SCHEMBL4206630 | 0.84 | F2 (0.33) | PARP1DPP4 | |
| SCHEMBL3648462 | 0.81 | SCN9A (0.36) | — | |
| SCHEMBL26635701 | 0.81 | SCN9A (0.36) | — | |
| SCHEMBL7494605 | 0.81 | GNAO1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227300-B1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2026-01-28 | — | — | EP | claimed |
| CN-118307496-A | Butanediamide antitumor compound and preparation method and application thereof | 江苏海洋大学 | 2024-07-09 | — | — | CN | claimed |
| EP-2766347-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-116348115-B | Combination of antibody-drug conjugate and PARP1 selective inhibitor | ASTRAZENECA UK LTD. (GB) | 2026-05-26 | — | — | CN | disclosed |
| CN-122079899-A | Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098683-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12617784-B2 | AKT inhibitor | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-12606566-B2 | Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| WO-1995000510-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 5-[2-(4-(BENZOISOTHIAZOL-3-YL)-PIPERAZIN-1-YL)ETHYL]-6-CHLORO-1,3-DIHYDRO-INDOL-2-ONE | PFIZER INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5372813-A | Measurement of serotonin uptake sites in a sample using a radio labeled substituted 6-nitroquipazine as a radioligand | THE REGENTS, UNIVERSITY OF CALIFORNIA (US) | 1994-12-13 | — | — | US | disclosed |
| US-5359068-A | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one | PFIZER INC. (US) | 1994-10-25 | — | — | US | disclosed |
| US-5342947-A | Treating alkylenedioxy-7-trihaloacetamidomethylenecamptothecin with hydrochloric or sulfuric acid to yield amine salt, treating with alkali metal hydroxide or carbonate to obtain free base | GLAXO INC. (US) | 1994-08-30 | — | — | US | disclosed |
| EP-0550566-A1 | ANTIPROLIFERATIVE SUBSTITUTED NAPHTHALENE COMPOUNDS | AGOURON PHARMACEUTICALS (US) | 1993-07-14 | — | — | EP | disclosed |
| EP-0540099-A1 | Water soluble camptothecin derivatives | GLAXO WELLCOME INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992005153-A1 | ANTIPROLIFERATIVE SUBSTITUTED NAPHTHALENE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1992-04-02 | — | — | WO | disclosed |
| US-4963680-A | INTERMEDIATES FOR THERAPEUTIC DRUGS | SYNTHELABO (FR) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617784-B2 | AKT inhibitor | AKT2, AKT1, AKT3 | PARP1 1111/4885DPP4 3261/4885 |
| US-12606566-B2 | Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors | BTK, LYN, SYK | PARP1 1270/4885DPP4 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.